Home

Results 1 - 10 of 141,689 for pharmaceutical corporations. Search took 25.479 seconds.  
Sort by date/Sort by relevance
ENTRANCE PHARMACEUTICALS AND RESEARCH CENTRE ENTRANCE PHARMACEUTICALS & RESEARCH CENTER INTRODUCTION VISION To be the Premium Provider of quality pharmaceutical products. (...) Tobinco Pharmaceuticals currently has a track record of selling 20% of Ghana's generic drugs market with distribution outlets and Networks all across Ghana. (...) CONCLUSION ◦ Entrance Pharmaceuticals & Research Centre your partner of choice for strategic pharma business in Ghana and the sub-region of Africa.
Language:English
Score: 1508153 - https://www.unido.org/sites/de...esentation_01032018%20Bonn.pdf
Data Source: un
Chief Executive OfficerChief Executive Officer DENALI BioTechnologies, LLCDENALI BioTechnologies, LLC Soldotna, AlaskaSoldotna, Alaska 8th Meeting of the UN Open-ended Informal Consultative Process on Oceans and the Law of the Sea DENALI DENALI BioTechnologiesBioTechnologies Alaska Marine and Forest Products • Modern utilization for commercial purposes based principally on the enduring wisdom of Alaska Natives – Subsistence foods and traditional medicines • In local industries these products typically marketed as: – Specialty wild food/menu items, jams/jellies, and confections – Teas and health-oriented beverage ingredients – Hand-crafted medicinals and tonics – Boutique cosmetics and personal care products – Home environment enhancing products • Beyond established commercial fisheries, new opportunity must derive from sustainablesustainable resources and supply chains for emerging large, high-value markets 2 • Develop Alaska’s exceptional wilderness and marine bioresources for high-quality: – Nutraceuticals – Cosmeceuticals – Phytopharmaceuticals (Herbals) – Pharmaceuticals • Promote bioresources with plentiful bona fide “bioactives” for improving health and quality of life • Create sustainable economic development from renewable resources, notably in underdeveloped rural areas, through environmentally-friendly processes DENALI DENALI BioTechnologiesBioTechnologies Denali’s Vision • Tremendous untapped opportunities exist for in large markets • Revenues from nutraceuticals – >$75BB by 2007 in U.S. – >$210BB globally, growing to >$310BB by 2010 – Adjusted annual growth rate of: • +9% for botanicals • +18% for fortified beverages • +22% for natural foods • +27% for functional food • Compare to ~$55 BB annual research commitment by major U.S. pharmaceutical companies Nutraceutical Industry Statistics DENALI DENALI BioTechnologiesBioTechnologies 3 Biodiversity Sources of Alaska • Inherent biodiversity in 20 USGS ecoregions – 6+ climatic zones (12 with maritime features) – Every major geologic period represented – Pre-ice age, unglaciated tracts; 10,000 extant glaciers – 89 volcanoes with hotsprings and boiling mudpots - Enormous metal and mineral deposits - 2 old-growth rainforest stands (33 MM acres) - 5 tundra types and bogs - Sea level to 20,300 feet - 33,000 miles of coastline DENALI DENALI BioTechnologiesBioTechnologies 4 Alaska’s Unique Environment • Vast Alaska wilderness and marine environments provide rich sources of novel commercial products • Result from extreme environmental stresses – Unusual species and novel molecules emerge through biochemical/genetic adaptation to harsh conditions • Biotic – Herbivory (mammals, birds, insects), microbial pathogens • Abiotic – Photoperiod length / UV exposure (60 days to 200 days) – Nutrient-poor soils, high levels of metals (e.g. arsenic) – Precipitation (150mm to 2500mm; 6 in. to 150 in.) – Temperature (-63oC to 35oC; -82oF to 95oF) • Most organisms are psychrophilic or cold-adapted DENALI DENALI BioTechnologiesBioTechnologies 5 Discovery Strategies • Random Bioprospecting – Small quantities of soils, sediments, coastline samples • Cultivable microbes and nucleic acid recovery from uncultivable organisms that yield enzymes/biocatalysts • Exclusively for pharmaceutical discovery • Targeted Bioprospecting – Focused collections of small amounts of plants, soils, sediments, etc. directed by chemotaxonomy, chemical ecology (abiotic/biotic stress), extreme conditions • Principally for pharmaceutical discovery or cosmeceuticals • Ethnopharmacology – Alaska Native traditional medicine and subsistence diets offer hundreds of plant, fungal, animal, and marine candidates for product R&D DENALI DENALI BioTechnologiesBioTechnologies Maximum Fieldwork Output Vascular/ Flowering Plants Mosses and Lichens Aquatic / Marine Organisms Microbial Isolates Soils/Sediments Extract / Purify / Analyze / Bioassay Small Molecules, Biopolymers, Genes, Enzymes Pharmaceuticals Phytopharmaceuticals Nutraceuticals (low abundance) Cosmeceuticals (high abundance) (moderate abundance) DENALI DENALI BioTechnologiesBioTechnologies 6 Discovery Strategies DENALI DENALI BioTechnologiesBioTechnologies • Random Bioprospecting – Small quantities of soils and sediments • Cultivable microbes and nucleic acid recovery from uncultivable organisms that yield enzymes/biocatalysts for pharmaceutical discovery • Targeted Bioprospecting – Focused collections of small amounts of plants, soils, sediments, etc. directed by chemotaxonomy, chemical ecology (abiotic/biotic stress), extreme conditions • Principally for pharmaceutical discovery or cosmeceuticals • Ethnopharmacology – Alaska Native traditional medicine and subsistence diets offer hundreds of plant, fungal, animal, and marine candidates for product R&D 7 Alaska Native Claims Settlement Act DENALI DENALI BioTechnologiesBioTechnologies • Alaska Natives extinguished sovereign rights to land and resources for $962.5 million in 1971 • ANCSA prevented formation of reservations after Alaska statehood was granted in 1959 – One reservation formed voluntarily (Metlakatla) and one tribal government / reserve (Venetie) • ~10% of Alaska land belongs to ANCSA entities – 13 Regional Corporations – subsurface rights – 200+ Village Corporations – surface / coastal access rights – Tribal councils advise on cultural issues; no economic status – Contrast to ~65% Federal, ~25% State, <1% private lands • Intended to provide for economic self-determination • Research and commercial development activities require access for bioprospecting of marine resources and non-timber forest products • Legal considerations involving ownership and compensation to government or landholder – Collaborating landholders are primarily Alaska Native corporations / tribal councils – Federal and State landholders governed by law • Denali (and predecessor companies) crafted the pioneering “Biodiversity Access Agreement” for Alaska – self-imposed code of ethics – Based on common sense and “Golden Rule” Bioprospecting Model DENALI DENALI BioTechnologiesBioTechnologies 8 “ Fair Treatment ” Agreement DENALI DENALI BioTechnologiesBioTechnologies • Denali’s version of the “Fair Trade” Agreement – New initiative introduced for consideration in May, 2007 – Targeted to accommodate diverse needs and expectations of Alaska Native organizations – Engage Federal and State agencies / landholders in active management beyond established protection laws – for responsible commercialization – of biodiversity and high- value marine bounty and non-timber forest products • Fundamental objectives: – Establish uniform system of access/utilization rights – Determine fair compensation for harvest • Critical for ability of corporate partners to compete in marketplace and generate revenues and economic development “ Fair Treatment ” Agreement DENALI DENALI BioTechnologiesBioTechnologies • More advanced considerations include: – Prioritization of rural villages in most critical need of economic opportunities for resource commercialization • Many have >70% unemployment, are on the brink of total bankruptcy, have no infrastructure including running water or sewer facilities, no clinics/dental services, etc. • Most advanced considerations include intellectual property (IP) rights of Alaska Natives • Denali created a means to convert side-by-side orally passed knowledge into scientific methodologies – No disclosure of spiritual or culturally sensitive information • Transform standard pharma/biotech industry royalty into more value for traditional knowledge 9 “ Fair Treatment ” Agreement DENALI DENALI BioTechnologiesBioTechnologies • Compensation criteria: – “Passive” access to land • Royalty on profits from commercialized product (0.5 - 2%) – “Guided” access to land • Profit-sharing (negotiated, up to 10%) – “Contributing” access to land and knowledge • Profit-sharing and patent rights (negotiated, up to 50%) • Incentives for responsible corporate partners who: – Pay appropriate prices for raw products – Local processing to add value in the State of Alaska – Create rural/local employment – Contribute financial support to determine/establish sustainability of resources and minimize footprint – Conduct/share research to identify valuable new resources Lessons from Alaska Natives • Before “Western” acculturation, very low prevalence of cardiovascular disease, diabetes and cancer • Most valuable for studies of “Nature vs. Nurture” – Cultures date to >15,000 YA – Role of diet in health/disease • Medicinal foods are staples in traditional Alaska Native diets • Traditional medicine is practiced and viable – Untapped information for pharmaceutical discovery • Impetus for developing flagship products – Abundant wild berries and rosehips – Future dietary supplements from other abundant subsistence foods, including fish (salmon), kelp, etc. DENALI DENALI BioTechnologiesBioTechnologies 10 Fish-Derived Product Line DENALI DENALI BioTechnologiesBioTechnologies • Functional food ingredients from pink salmon – Market collapsed for canned product • Hatcheries throughout Alaska yield millions of unconsumed fish and rural streams are chock full while villagers “starve” – New market for RWD product with mild flavor and high essential nutrient content (i.e. omega-3 fatty acids) • Particular value for infant formula/food, enteral formulations, etc. • “Waste” flesh and racks for calcium supplement – Natural bone provides Ca++, Mg++ and trace minerals along with Vitamin D, omega-3 fatty acids, and astaxanthin – Utilize millions of pounds of biomass instead of dumping • Discarded roe is excellent source of nutrients • Skin/scales used in cosmetics DENALI DENALI BioTechnologiesBioTechnologies Side View of Refractance Window® Drier (RWD) 11 Dried Salmon Roe Flakes Exiting Drier Belt DENALI DENALI BioTechnologiesBioTechnologies Marine Mammal PUFA Project DENALI DENALI BioTechnologiesBioTechnologies • Key observations and drivers: – Alaska Natives who consume high quantities of marine mammal fat (coastal populations) do not suffer from high rates of central nervous system (CNS) disease or depression – Interior populations tend to be more prone to depression • To find the reason, seal oil prepared in a traditional manner as food is under analysis for novel essential polyunsaturated fatty acids (PUFA) – Many novel PUFA in addition to EPA and DHA – Compare / contrast to common salmon PUFA • Enzymatically convert common salmon PUFA to novel seal PUFA, separate, and screen for CNS effects 12 Future Challenges DENALI DENALI BioTechnologiesBioTechnologies • Sustainability of marine and non-timber resources – Identify those appropriate for desired market • Nutraceuticals demand abundant resources and harvest volume • Cosmeceuticals consume far less resources (~10% of above) • Pharmaceuticals require very limited harvest and footprint • Protect high intrinsic resource value during processing • Supply chains – Determine fair prices for harvest • Critical for ability to compete in marketplace – Develop efficient logistical, transport and storage strategies • Minimize spoilage/waste and control shipping costs • Establish priority villages for commercial partnerships Contact Information Maureen A.
Language:English
Score: 1497556.9 - https://www.un.org/depts/los/c...ocess/documents/8_mckenzie.pdf
Data Source: un
The International Federation of Pharmaceutical Manufacturers and Associations declared a conflict of interest. One of their national pharmaceutical associations has a member whose business includes tobacco products. (...) In addition, the International Federation of Pharmaceutical Manufacturers and Associations reported a conflict of interest. 36.
Language:English
Score: 1494946.3 - https://www.who.int/fctc/cop/cop7/FCTC_COP_7_28_EN.pdf
Data Source: un
Project Publications Pharmaceutical Sector | UNIDO Skip to main content quick access For Member States Employment Procurement For researchers Publications Statistical databases Research services Director General Quick Access Main navigation Who we are Who we are UNIDO in brief 2030 Agenda and the SDGs Inclusive and Sustainable Industrial Development Third Industrial Development Decade for Africa UNIDO Worldwide Director General Our focus Our focus Creating shared prosperity Advancing economic competitiveness Safeguarding the environment Strengthening Knowledge and Institutions Cross-cutting services Building a better future UNIDO’s normative role for higher impact Stories News Centre News Centre News articles Events Multimedia Resources Resources Policymaking Organs Evaluation and Internal Oversight Procurement Statistics Publications Employment Home Our focus Advancing economic compet... (...) Competitiveness, business... Pharmaceutical production Publications Sidebar - Our focus Creating shared prosperity Advancing economic competitiveness Upgrading businesses and industrial infrastructure Investing in technology and innovation Investment and technology Competitiveness, business environment and upgrading Information and communications technology Pharmaceutical production Publications Events Technology foresight Supporting small and medium industry clusters Setting up and supporting export consortia Meeting the standards Quality and compliance infrastructure Competitive trade capacities and corporate responsibility Entrepreneurship development Branding for Competitiveness and Sustainable Growth Industrial Design for Sustainable Development Safeguarding the environment Strengthening Knowledge and Institutions Cross-cutting services Building a better future UNIDO’s normative role for higher impact Project Publications Pharmaceutical Sector Building a Successful Vaccine Manufacturing Business in Lower and Middle Income Countries Download Pharmaceutical Industry in Sub-Saharan Africa A Guide for Promoting Pharmaceutical Production in Africa Download Boosting Pharmaceutical Production Brochure (English) Brochure (French) Project Fact Sheet (English) Project Fact Sheet (French) White Paper on Commercialising Vaccines: A Methodology to Identify Potential Market Opportunities and Conduct Outline Assessments Case study: South Africa Download Sector Development Strategy for Pharmaceutical Manufacturing in Zimbabwe (2017-2022) Download White Paper on Establishing Manufacturing Capabilities for Human Vaccines Key cost drivers and factors to consider when planning the establishment of a vaccine production facility Download Vaccine Manufacturing and Procurement in Africa An analytical assessment of vaccine manufacturing capacity and procurement mechanisms for establishing sustainable vaccine manufacturing capacity in Africa Download White Paper on UNIDO's GMP Roadmap Concept Design of a stepwise approach for the pharmaceutical industry in developing countries to comply with WHO GMP Download Analysis of Training Needs in the Generic Medicines Sector in the South African Development Community Study commissioned by the Southern African Generic Medicines Association Download Pharmaceutical Manufacturing Plan for Africa Business plan Arabic English French Portuguese Footer Who we are UNIDO in brief History UNIDO Worldwide Director General Our focus UNIDO & the SDGs Inclusive and Sustainable Industrial Development Programme for Country Partnership Third Industrial Development Decade for Africa GMIS - Global Manufacturing & Industrialisation Summit Explore Projects Stories News Publications More Employment Procurement Legal Resources Scam Alert Evaluation and Internal Oversight Report Wrongdoing Contact Information Press and Media Disclaimer © 2017 United Nations Industrial Development Organization
Language:English
Score: 1456390.5 - https://www.unido.org/our-focu...ications-pharmaceutical-sector
Data Source: un
Teva Pharmaceutical Industries Ltd – Teva Pharmaceuticals CSR Report 2012 | UN Global Compact All Participants Search Who We Are The SDGs Participation Take Action Engage Locally Explore Our Library About News Sign In Contact Us Communication on Progress In this section Participation Getting Started Why Join Reporting Communication on Progress Communication on Engagement Teva Pharmaceuticals CSR Report 2012 Participant Teva Pharmaceutical Industries Ltd Published 2013/10/16 Time period January 2012  –  October 2013 Files TevaPharmaceuticals_CSR REPORT_UNGC_COP_2012_Oc... (English) Format Part of a sustainability or corporate (social) responsibility report Differentiation Level This COP qualifies for the Global Compact Active level Self-assessment Includes a CEO statement of continued support for the UN Global Compact and its ten principles Description of actions or relevant policies related to Human Rights Description of actions or relevant policies related to Labour Description of actions or relevant policies related to Environment Description of actions or relevant policies related to Anti-Corruption Includes a measurement of outcomes Note: Responsibility for the content of participants' public communication related to the Ten Principles of the UN Global Compact and their implementation lies with participants themselves and not with the UN Global Compact.
Language:English
Score: 1448686.5 - https://www.unglobalcompact.or...create-and-submit/active/38371
Data Source: un
International Business and Investment Forum 2 Introduction • Helping leading companies advance complex business interests in more than 160 countries • Working across a highly integrated platform of more than 1,000 lawyers in 20 offices globally • Delivering tailored commercial solutions through world-class offerings and an uncompromising approach to quality and service International Business and Investment Forum 3 About King & Spalding • More than 300 lawyers and professionals located in nine offices • Representation of more than 200 pharmaceutical, biotechnology and medical device manufacturers • Specialized experience at every stage of the product life cycle • Ability to represent clients in cross-border transactions around the world • Substantive expertise, bench strength and collaborative approach to client service International Business and Investment Forum 4 Our Life Sciences Practice Globally Counseling on • International Compliance Standards • Protection against Falsified Products • Protection against Foreign Corruption • Intellectual Property • Capital-raising Transactions • License • Corporate Partnering Agreements • Clinical Trials • Marketing Approval • Manufacturing • Marketing & Advertising • Commercial and Post-Approval Regulatory International Business and Investment Forum 5 Our Life Sciences Practice Globally • Strategic M&A • Litigation & Arbitration • Government and Internal Investigation • Distribution • Unfair Competition • International Trade • Recalls International Business and Investment Forum 6 Our Life Sciences Practice Globally 7 Our International Offices  London  Frankfurt  Geneva  Paris  Abu Dhabi  Dubai  Riyadh  Singapore  Atlanta  Austin  Charlotte  Chicago  Houston  Los Angeles  New York  San Francisco  Silicon Valley  Washington, D.C.  Moscow  Tokyo International Business and Investment Forum International Business and Investment Forum 8 Ulf Grundmann specializes in regulations and compliance regarding the pharmaceutical, medical devices, cosmetic and food industries, and in litigation in the European Union. As partner in our FDA and Life Sciences practice, he has an additional focus on corporate and financial transactions for life science industries. (...) She advises and represents clients in the medical device, pharmaceutical, cosmetics and food industries on legal aspects in every stage of the life cycle of a product, including product development, labeling, advertising, distribution, compliance, data protection, aspects related to parallel importation, protection against falsified products, recalls, if necessary and end-of-life.
Language:English
Score: 1442151.8 - https://www.unido.org/sites/de...esentation_01032018%20Bonn.pdf
Data Source: un
EB Document Format Conference of the Parties to the WHO Framework Convention on Tobacco Control Seventh session Delhi, India, 712 November 2016 12 November 2016 DECISION FCTC/COP7(16) Review of accreditation of nongovernmental organizations with the status of observer to the Conference of the Parties The Conference of the Parties, Recalling 17th and 18th preambular paragraphs and Article 5.3 of the Convention; Recalling decisions FCTC/COP2(6), FCTC/COP4(23), FCTC/COP5(22) and FCTC/COP/6/26; Having considered the proposals contained in document FCTC/COP/7/28, DECIDES, in accordance with Rule 31.3 of its Rules of Procedure: (a) to maintain the observer status of the following 17 nongovernmental organizations (NGOs) that submitted a report: Campaign for Tobacco-Free Kids; Corporate Accountability International; European Network for Smoking and Tobacco Prevention; FDI World Dental Federation; Framework Convention Alliance on Tobacco Control; International Alliance of Women; International Council of Nurses; International Network of Women Against Tobacco; International Pharmaceutical Federation; International Pharmaceutical Students’ Federation; International Union Against Tuberculosis and Lung Disease (the Union); Southeast Asia Tobacco Control Alliance; Union for International Cancer Control; World Federation of Public Health Associations; World Heart Federation; World Medical Association; World Self-Medication Industry; (b) to discontinue the observer status of two NGOs (International Federation of Pharmaceutical Manufacturers and Associations and Medical Women’s International Association), since their WHO FCTC-related activities are minimal. In addition, the International Federation of Pharmaceutical Manufacturers and Associations reported a conflict of interest; (c) to discontinue the observer status of Consumers International, for the reasons outlined in paragraph 5 of FCTC/COP/7/28.
Language:English
Score: 1441088.9 - https://www.who.int/fctc/cop/cop7/FCTC_COP7_16_EN.pdf
Data Source: un
Leisinger |February 23,.2009 | 2| Business Use Only Make profits and comply with applicable laws and regulations Corporate Responsibility beyond legal duties: Live up to the spirit of international norms Corporate philanthropy and pro bono work Desirable (can) Expected (ought to) Essentials (must) Corporate responsibility excellence Good management practices The hierarchy of corporate responsibilities ECOSOC Special Event on Philanthropy and The Global Public Health Agenda - Klaus M. (...) Leisinger |February 23,.2009 | 9| Business Use Only Issues for Corporate Reflection What is a fair and sustainable corporate contribution to improvements of the access to medicines under conditions of market failure? (...) Corporate Responsibilities forAccess to Medicines ECOSOC Special Event onPhilanthropy and the Global Public Health Age The hierarchy of corporate responsibilities The societal return on pharmaceutical core competence The hierarchy of corporate responsibilities: The “ought to” - Dimension Fighting poverty: A call for action to all responsible citizens Corporate Responsibility Tools to improve„Access to Medicine“ under conditions of market failure The hierarchy of corporate responsibilities: The “can” - Dimension Poly-contextural issues necessitate „multi-stakeholder-solution teams“
Language:English
Score: 1427462.9 - https://www.un.org/en/ecosoc/phlntrpy/docs/leisinger.pdf
Data Source: un
WHO | NGOs reports 2016 Access Home Alt+0 Content Alt+2 Search Navigation Home Convention Protocol Secretariat Treaty instruments Coordination platform Reporting Media centre Language عربي 中文 English Français Русский Español Menu WHO FCTC Parties Governance Assessed contributions Declaration of interest Global Strategy 2025 NGOs reports 2016 Campaign for Tobacco-Free Kids pdf, 28kb Corporate Accountability International pdf, 29kb European Network for Smoking and Tobacco Prevention pdf, 32kb FDI World Dental Federation pdf, 20kb Framework Convention Alliance on Tobacco Control pdf, 36kb International Alliance of Women pdf, 21kb International Council of Nurses pdf, 128kb International Federation of Pharmaceutical Manufacturers & Associations pdf, 24kb International Network of Women Against Tobacco pdf, 25kb International Pharmaceutical Federation pdf, 43kb International Pharmaceutical Students' Federation pdf, 24kb International Union Against Tuberculosis and Lung Disease pdf, 32kb Medical Women's International Association pdf, 19kb Southeast Asia Tobacco Control Alliance (SEATCA) pdf, 31kb Union for International Cancer Control pdf, 50kb World Federation of Public Health Associations pdf, 36kb World Heart Federation pdf, 30kb World Medical Association pdf, 32kb World Self-Medication Industry pdf, 40kb NGOs news You are here: WHO Framework Convention on Tobacco Control Quick Links Resources Contacts Employment Sitemap Convention Protocol Secretariat Treaty Instruments Coordination Platform Reporting Media Centre Index Topics © WHO 2022
Language:English
Score: 1423090.3 - https://www.who.int/fctc/cop/ngo-reports/en/
Data Source: un
Webinar: Opportunities in African Pharmaceutical Markets | UNIDO Skip to main content quick access For Member States Employment Procurement For researchers Publications Statistical databases Research services Director General Quick Access Main navigation Who we are Who we are UNIDO in brief 2030 Agenda and the SDGs Inclusive and Sustainable Industrial Development Third Industrial Development Decade for Africa UNIDO Worldwide Director General Our focus Our focus Creating shared prosperity Advancing economic competitiveness Safeguarding the environment Strengthening Knowledge and Institutions Cross-cutting services Building a better future UNIDO’s normative role for higher impact Stories News Centre News Centre News articles Events Multimedia Resources Resources Policymaking Organs Evaluation and Internal Oversight Procurement Statistics Publications Employment Home Our focus Advancing economic compet... (...) Competitiveness, business... Pharmaceutical production Events Sidebar - Our focus Creating shared prosperity Advancing economic competitiveness Upgrading businesses and industrial infrastructure Investing in technology and innovation Investment and technology Competitiveness, business environment and upgrading Information and communications technology Pharmaceutical production Publications Events Webinar: Opportunities in African Pharmaceutical Markets 2018 Africa Industrialization Day UNIDO International Business and Investment Forum 2018 Technology foresight Supporting small and medium industry clusters Setting up and supporting export consortia Meeting the standards Quality and compliance infrastructure Competitive trade capacities and corporate responsibility Entrepreneurship development Branding for Competitiveness and Sustainable Growth Industrial Design for Sustainable Development Safeguarding the environment Strengthening Knowledge and Institutions Cross-cutting services Building a better future UNIDO’s normative role for higher impact Webinar: Opportunities in African Pharmaceutical Markets Webinar Announcement As part of our work to promote stronger linkages between African and European pharmaceutical firms, UNIDO will host a webinar to provide a brief overview of the pharmaceutical markets in Sub-Saharan Africa.  (...) In Africa, our efforts have included activities to: Assist countries to develop and implement pharmaceutical sector development strategies Increase capabilities of local pharmaceutical manufacturers via training Promote access to technical expertise, finance and linkages by facilitating  partnerships Footer Who we are UNIDO in brief History UNIDO Worldwide Director General Our focus UNIDO & the SDGs Inclusive and Sustainable Industrial Development Programme for Country Partnership Third Industrial Development Decade for Africa GMIS - Global Manufacturing & Industrialisation Summit Explore Projects Stories News Publications More Employment Procurement Legal Resources Scam Alert Evaluation and Internal Oversight Report Wrongdoing Contact Information Press and Media Disclaimer © 2017 United Nations Industrial Development Organization
Language:English
Score: 1419504 - https://www.unido.org/our-focu...african-pharmaceutical-markets
Data Source: un